[go: up one dir, main page]

MXPA01011344A - El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. - Google Patents

El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.

Info

Publication number
MXPA01011344A
MXPA01011344A MXPA01011344A MXPA01011344A MXPA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A
Authority
MX
Mexico
Prior art keywords
prophylactic
tyrosine kinase
protein tyrosine
kinase pathway
therapeutic treatment
Prior art date
Application number
MXPA01011344A
Other languages
English (en)
Spanish (es)
Inventor
Juan Eugene De Jr
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of MXPA01011344A publication Critical patent/MXPA01011344A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
MXPA01011344A 1999-05-07 2000-05-05 El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. MXPA01011344A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13311299P 1999-05-07 1999-05-07
US35044099A 1999-07-09 1999-07-09
PCT/US2000/012339 WO2000067738A2 (fr) 1999-05-07 2000-05-05 Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires

Publications (1)

Publication Number Publication Date
MXPA01011344A true MXPA01011344A (es) 2004-06-03

Family

ID=26831056

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011344A MXPA01011344A (es) 1999-05-07 2000-05-05 El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.

Country Status (6)

Country Link
EP (1) EP1178791A2 (fr)
JP (1) JP4920134B2 (fr)
AU (1) AU774495B2 (fr)
CA (1) CA2373178C (fr)
MX (1) MXPA01011344A (fr)
WO (1) WO2000067738A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
EP1962803A1 (fr) * 2005-12-23 2008-09-03 Alcon, Inc. Preparation pharmaceutique pour l'administration de composes recepteurs inhibiteurs de la tyrosine kinase (rtki) dans l'oeil
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
CN111655151B (zh) * 2018-01-25 2024-03-22 国立大学法人大阪大学 压力状态的检测方法以及压力检测装置
CN114931574A (zh) * 2022-06-14 2022-08-23 深圳爱尔眼科医院 一种铁死亡抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316000A (ja) * 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
DE69734290T2 (de) * 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
WO1998040090A1 (fr) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methodes d'inhibition de cytotoxicite bacterienne
AU744939B2 (en) * 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2321560C (fr) * 1998-03-13 2007-05-22 Johns Hopkins University School Of Medicine Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine

Also Published As

Publication number Publication date
WO2000067738A3 (fr) 2001-08-23
CA2373178A1 (fr) 2000-11-16
WO2000067738A2 (fr) 2000-11-16
JP4920134B2 (ja) 2012-04-18
AU774495B2 (en) 2004-07-01
CA2373178C (fr) 2013-07-02
EP1178791A2 (fr) 2002-02-13
AU4988400A (en) 2000-11-21
JP2002544159A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
CA2321560A1 (fr) Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine
MX2010003774A (es) Formulaciones oftalmicas acuosas.
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
CO2022000659A2 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
CA2502437A1 (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
BR0312232A (pt) Inibidores de caspases e seus usos
ES2159209T3 (es) Uso de acido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz(b,e)oxepin-2-acetico y de sus sales farmaceuticamente aceptables para la fabricacion de un medicamento para el tratamiento de trastornos oftalmicos no alergicos y para la prevencion de neovascularizacion ocular.
CA2582316A1 (fr) Utilisation d'inhibiteurs de jun n-terminal kinases pour le traitement de la retinopathie glaucomateuse et de maladies oculaires
MXPA01011344A (es) El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
CA2314571A1 (fr) Methodes et compositions pour traiter des maladies et des affections de l'oeil
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
WO2006039252A3 (fr) Compositions et methodes de traitement de maladies ophtalmiques
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2007004030A (es) Analogos de poliamina como agentes terapeuticos para enfermedades oculares.
EP1037622A4 (fr) Derives de la taurine pour le traitement de troubles ophtalmiques
MXPA03001160A (es) Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico.
WO2005102303A3 (fr) Antiprostaglandines pour le traitement de pathologies oculaires
CY1108572T1 (el) Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο
IT1276462B1 (it) Diamidi aromatiche acide ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico
DK1161256T3 (da) Anvendelse af nervevækstfaktor til fremstilling af et medikament til terapi af intraokulære vævspatologier
BR0114339A (pt) Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
PT1259229E (pt) Utilizacao de benzotieno-[2,3-d]-pirimidinas com uma accao inibidora da pde v no tratamento do disfuncao erectil
ES2289134T3 (es) Uso de estrogenos no feminizantes como agentes protectores de la retina para el tratamiento del glaucoma.

Legal Events

Date Code Title Description
FG Grant or registration